Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: He, Yundong, Peng, Shihong, Wang, Jinhua, Chen, Huang, Cong, Xiaonan, Chen, Ang, Hu, Meichun, Qin, Min, Wu, Haigang, Gao, Shuman, Wang, Liguo, Wang, Xin, Yi, Zhengfang, Liu, Mingyao
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5159881/
https://ncbi.nlm.nih.gov/pubmed/27959342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13122
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires